Mr. Marc Edwards reports

KANE BIOTECH ANNOUNCES CLOSING OF THE SALE OF STEM ANIMAL HEALTH TO DECHRA VETERINARY PRODUCTS

Kane Biotech Inc. has completed the sale of its interest in STEM Animal Health Inc. to Dechra Veterinary Products Inc. for $8-million (U.S.), plus net cash held in STEM (estimated at $600,000 (Canadian)) and a working capital adjustment (estimated at $350,000 (Canadian)). Overall, it is anticipated that the sale of STEM will net Kane an estimated CND $11,500,000. The Transaction was completed by way of a share purchase agreement between Kane, STEM, Ecuphar NV and Dechra dated April 12, 2024.

"This transaction not only allows Dechra to continue to deliver our best-in-class Vetradent pet oral care line, but also provides a significant opportunity to expand our offerings in the e-commerce and pet specialty markets in North and South America as well by leveraging both Kane's expertise and their proven and patented coactiv+(TM) and DispersinB(TM) technology platforms in a broad range of products and treatments," said Mike Eldred, President, North American Operations of Dechra.

In connection with the Transaction, Kane also entered into a product development agreement, and a transitional manufacturing agreement with STEM. Kane is also eligible for a US $750,000 sales-based milestone payment if certain sales targets are met by STEM.

"This transaction, which should ultimately net Kane more than $13 million CND, is an important step in Kane becoming a market leader in the growing high-value wound care and dermatological market," said Marc Edwards, Kane's President and CEO. "It focuses the company, significantly improves our balance sheet and provides the necessary capital to achieve key milestone such as commercial launches and growth globally, as well as our clinical programs in both wound care and acne."

Prior to the completion of the Transaction, Kane received an aggregate of US $1,525,000 from Dechra as deposits towards the final purchase price.

In connection with the completion of the Transaction, a portion of the net proceeds will be used to repay its loan from Pivot Financial I Limited Partnership of approximately CND $6.7 million.

In accordance with the policies of the TSX Venture Exchange, the Transaction required the consent of shareholders of Kane holding over 50% of the common shares of Kane due to the fact that the Transaction constituted a sale of more than 50% of Kane's assets, business or undertaking. In connection with the completion of the Transaction, Kane obtained the written consent of shareholders of Kane holding more than 50% of the common shares of Kane.

In connection with the Transaction, Research Capital Corporation acted as Kane's financial advisor and was paid an advisory fee of approximately CND $120,000. Research Capital is not a Non Arm's Length Party to Kane and no securities of Kane were issued in connection with the Transaction. The Transaction has received the approval of a majority of Kane's shareholders and the conditional approval of the TSX Venture Exchange. The Transaction remains subject to the final approval of the TSX Venture Exchange.

About Kane Biotech

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. StrixNB(TM), DispersinB(TM), Aledex(TM), bluestem(TM), bluestem(TM), silkstem(TM), goldstem(TM), coactiv+(TM), coactiv+(TM), DermaKB(TM), DermaKB Biofilm(TM), and revyve(TM) are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol "KNBIF".

We seek Safe Harbor.